NICE to appraise Bracco's contrast-enhanced ultrasound tech
This article was originally published in Clinica
Executive Summary
The UK’s National Institute for Health and Clinical Excellence (NICE) is to appraise the contrast-enhanced ultrasound imaging agent SonoVue under its diagnostics health technology assessment (HTA) pathway. Manufacturers of rival products should note that the appraisal will also cover “other alternative technologies identified during scoping”. The schedule for the appraisal has not been announced yet. SonoVue – sulphur hexafluoride microbubbles – was developed by Bracco Diagnostics (Milan, Italy) and was launched in the EU in 2001.